No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis

Jafari, Naghmeh; Nierop, Gijsbert P. van; Verjans, Georges M. G. M.; Osterhaus, Albert D. M. E.; Middeldorp, Jaap M.; Hintzen, Rogier Q.

doi:10.1016/j.jcv.2010.06.007

Cited by 42 publications

(44 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, no statistically significant difference in the anti-EBNA IgG antibody-positive rate was found by Villegas et al [13] (6.6% in MS patients and 17.0% in OND) and by Castellazzi et al [14] (6.3% MS and 1.3% in OND). In addition, Pohl et al [15] showed that the anti-EBNA IgG antibody-positive rate of MS patients was 8%, similar to observations by Sargsyan et al [16] and Jafari et al [17] Our results support the above conclusions, but we found the anti-EBNA IgG antibody-positive rate was much higher than in these previous research reports. This difference may be explained by (1) different sample sizes, (2) the IFA used in our experiment which has a higher sensitivity than the ELISA assay in the previous studies, and (3) the EBV infection rate in China is higher than in European and American countries with better sanitary conditions.…”

Section: Discussionsupporting

confidence: 92%

Detection of Epstein-Barr virus infection subtype in patients with multiple sclerosis by indirect immunofluorescence assay

Zhang

Liu

Wang

et al. 2014

Neuroimmunol Neuroinflammation

View full text Add to dashboard Cite

Aim:The aim was to investigate the infectious conditions of Epstein-Barr virus (EBV) in patients with multiple sclerosis (MS). Methods: Cerebrospinal fluid (CSF) of 20 patients with MS and 20 with other neurological diseases (OND) were tested with indirect immunofluorescence for anti-EBV capsid antigen (EBV-CA) immunoglobulin G (IgG), IgG affinity for anti-EBV-CA, anti-EBV-CA immunoglobulin M (IgM), anti-EBV early antigen (EBV-EA) IgG and anti-EBV nuclear antigen (EBNA) IgG. According to the pattern of antibodies in CSF, infection rates of acute, chronic, primary, recurrent, and past infections were analyzed in the two groups of patients. Results: There were no significant differences in anti-EBV-CA, anti-EBC-EA, and anti-EBNA antigen IgG in CSF between MS and OND patients (P > 0.05). The positive rate of low affinity for anti-EBV-CA IgG in MS patients was significantly higher than that for OND patients (75% vs. 40%, P < 0.05). Furthermore, significant differences in the positive rate of anti-EBV-CA IgM were found between MS and OND patients (70% vs. 25%, P < 0.05). Of the MS patients, 75% were in an EBV acute infection state compared with 40% of OND patients (P < 0.05). Conclusion: Acute infection of EBV closely correlates with the occurrence of MS.

show abstract

Section: Discussionsupporting

confidence: 92%

Detection of Epstein-Barr virus infection subtype in patients with multiple sclerosis by indirect immunofluorescence assay

Zhang

Liu

Wang

et al. 2014

Neuroimmunol Neuroinflammation

View full text Add to dashboard Cite

show abstract

“…Many patients with systemic autoimmune diseases have elevated antibody levels to VCA and frequently EA(D) as well, suggesting virus involvement in the pathogenesis, or merely loss of immunological control, which is confirmed by parallel presence of elevated levels of EBV DNA in the circulation (Balandraud et al 2004;Poole et al 2009;James and Robertson 2012;Fattal et al 2014). Patients with multiple sclerosis tend to have an elevated IgG response to a defined domain in EBNA1, but not to other EBV antigens, which may suggest a pathogenic (mimicry) link (Munger et al 2011;Jafari et al 2010;Ruprecht et al 2014).…”

Section: Ebv Humoral Immune Responses As Defined By Classic Serology mentioning

confidence: 97%

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Middeldorp

2015

Current Topics in Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is widely distributed in the world and associated with a still increasing number of acute, chronic, malignant and autoimmune disease syndromes. Humoral immune responses to EBV have been studied for diagnostic, pathogenic and protective (vaccine) purposes. These studies use a range of methodologies, from cell-based immunofluorescence testing to antibody-diversity analysis using immunoblot and epitope analysis using recombinant or synthetic peptide-scanning. First, the individual EBV antigen complexes (VCA , MA, EA(D), EA(R) and EBNA) are defined at cellular and molecular levels, providing a historic overview. The characteristic antibody responses to these complexes in health and disease are described, and differences are highlighted by clinical examples. Options for EBV vaccination are briefly addressed. For a selected number of immunodominant proteins, in particular EBNA1, the interaction with human antibodies is further detailed at the epitope level, revealing interesting insights for structure, function and immunological aspects, not considered previously. Humoral immune responses against EBV-encoded tumour antigens LMP1, LMP2 and BARF1 are addressed, which provide novel options for targeted immunotherapy. Finally, some considerations on EBV-linked autoimmune diseases are given, and mechanisms of antigen mimicry are briefly discussed. Further analysis of humoral immune responses against EBV in health and disease in carefully selected patient cohorts will open new options for understanding pathogenesis of individual EBV-linked diseases and developing targeted diagnostic and therapeutic approaches.

show abstract

“…The GA-rich region has been described as the primary target of the normal peripheral humoral immune response (92)(93)(94)(95)97). This is verified by our data.…”

Section: Cryab: Igg Binding the N-terminal Region Maymentioning

confidence: 99%

High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients

Hecker

Fitzner

Wendt

et al. 2016

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Intrathecal immunoglobulin G (IgG Multiple sclerosis (MS)1 is a chronic disease of the central nervous system (CNS) that typically affects young adults, especially women. The disease is characterized by discrete areas of inflammation (lesions), demyelination, axonal loss, and astrogliosis in the brain and spinal cord. The clinical correlate of these processes is a wide range of neurological signs and symptoms involving mobility problems, vision problems, cognitive dysfunction, fatigue, and pain (1, 2). This

show abstract

No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis

Cited by 42 publications

References 33 publications

Detection of Epstein-Barr virus infection subtype in patients with multiple sclerosis by indirect immunofluorescence assay

Detection of Epstein-Barr virus infection subtype in patients with multiple sclerosis by indirect immunofluorescence assay

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients

Contact Info

Product

Resources

About